Heron Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Heron Therapeutics is Craig Collard, benoemd in Apr2023, heeft een ambtstermijn van 1.58 jaar. bezit rechtstreeks 0.18% van de aandelen van het bedrijf, ter waarde $ 472.07K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.4 jaar en 3.2 jaar.

Belangrijke informatie

Craig Collard

Algemeen directeur

US$5.5k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.6yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	1.4yrs
Gemiddelde ambtstermijn bestuur	3.2yrs

Recente managementupdates

Recent updates

Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%

Aug 08

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

May 30

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Apr 16

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Mar 15

Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 15

Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Dec 22

Need To Know: Analysts Just Made A Substantial Cut To Their Heron Therapeutics, Inc. (NASDAQ:HRTX) Estimates

Aug 11

Shareholders May Be A Bit More Conservative With Heron Therapeutics, Inc.'s (NASDAQ:HRTX) CEO Compensation For Now

Jun 11

CEO

Craig Collard (58 yo)

1.6yrs

Tenure

US$5,486

Compensatie

Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Craig Collard	CEO & Director	1.6yrs	US$5.49k	0.18% $ 472.1k
Ira Duarte	Executive VP & CFO	1.4yrs	US$1.76m	0.071% $ 191.2k
William Forbes	Executive VP & Chief Development Officer	1.4yrs	US$1.71m	0.068% $ 182.5k
Ryan Craig	Vice President of Marketing	1.3yrs	geen gegevens	geen gegevens
Sean Ristine	Senior Vice President of Human Resources	9.2yrs	geen gegevens	geen gegevens
Robert Sullivan	Senior Vice President of Oncology Care Franchise & Commercial Operations	1.8yrs	geen gegevens	geen gegevens
Brett Fleshman	Chief Business Officer	less than a year	geen gegevens	geen gegevens
Jeff Cohn	Executive Director	no data	geen gegevens	geen gegevens

1.4yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van HRTX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Craig Collard	CEO & Director	1.8yrs	US$5.49k	0.18% $ 472.1k
Craig Johnson	Independent Director	10.8yrs	US$11.02m	0.034% $ 91.8k
Christian Waage	Independent Director	8.4yrs	US$70.51k	0.034% $ 92.5k
Michael Kaseta	Director	no data	geen gegevens	geen gegevens
Susan Rodriguez	Independent Director	3.2yrs	US$65.63k	0.035% $ 93.7k
Adam Morgan	Independent Chairman	1.8yrs	US$545.53k	0.0062% $ 16.8k
Sharmila Dissanaike	Independent Director	3.2yrs	US$55.00k	0.035% $ 93.7k

3.2yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HRTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Heron Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Heron Therapeutics, Inc. Announces Appointment of Michael Kaseta to Board of Directors

Heron Therapeutics, Inc. Appoints Brett Fleshman as Chief Business Officer

Heron Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023

CEO & Director recently bought US$138k worth of stock

Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company

Recent updates

Heron Therapeutics, Inc. Announces Appointment of Michael Kaseta to Board of Directors

Heron Therapeutics, Inc. Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Heron Therapeutics, Inc. Appoints Brett Fleshman as Chief Business Officer

Consensus EPS estimates fall by 22%

Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%

Forecast breakeven date pushed back to 2026

Second quarter 2024 earnings: EPS misses analyst expectations

Heron Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Heron Therapeutics, Inc. Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Heron Therapeutics, Inc. Announces Acceptance of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Heron Therapeutics, Inc. Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

Consensus estimates of losses per share improve by 58%

Forecast breakeven date moved forward to 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Heron Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Heron Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Consensus estimates of losses per share improve by 51%

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Heron Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Price target decreased by 8.7% to US$6.67

Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Forecast to breakeven in 2026

Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023

Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Consensus EPS estimates upgraded to US$0.90 loss

CEO & Director recently bought US$138k worth of stock

Price target decreased by 13% to US$6.50

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024

Heron Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Market cap size

Consensus EPS estimates fall by 30%

Second quarter 2023 earnings: EPS misses analyst expectations

Heron Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Executive Vice President and Chief Development Officer

Heron Therapeutics, Inc. Announces Management Changes

Consensus EPS estimates fall by 17%

First quarter 2023 earnings: EPS misses analyst expectations

Heron Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Rubric Capital Management Engages with Heron Therapeutics

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Provides Sales Guidance for the Full Year 2023

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Announces the Submission of Supplemental New Drug Application for ZYNRELEF

Price target decreased to US$10.08

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Heron Therapeutics, Inc. Provides Sales Guidance for the Year 2022

Heron Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Heron Therapeutics, Inc. Announces U.S. FDA Approval of APONVIE™ (HTX-019) for Prevention of Postoperative Nausea and Vomiting

Heron wins FDA nod for post-operative agent to address nausea and vomiting

Heron Therapeutics, Inc. announced that it has received $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Heron Therapeutics, Inc. announced that it expects to receive $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC and other investors

Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?

Heron Therapeutics Q2 2022 Earnings Preview

Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan

Price target decreased to US$17.08

Heron Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

Heron Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022